Literature DB >> 33168738

Excess of the NF-ĸB p50 subunit generated by the ubiquitin ligase KPC1 suppresses tumors via PD-L1- and chemokines-mediated mechanisms.

Yelena Kravtsova-Ivantsiv1, Gilad Goldhirsh1, Alexandra Ivantsiv1, Ofer Ben Itzhak1,2, Yong Tae Kwon3, Eli Pikarsky4, Aaron Ciechanover5.   

Abstract

Nuclear factor-ĸB (NF-ĸB) transcription factor is a family of essential regulators of the immune response and cell proliferation and transformation. A typical factor is a heterodimer made of either p50 or p52, which are limited processing products of either p105 or p100, respectively, and a member of the Rel family of proteins, typically p65. The transcriptional program of NF-ĸB is tightly regulated by the composition of the dimers. In our previous work, we demonstrated that the ubiquitin ligase KPC1 is involved in ubiquitination and proteasomal processing of p105 to generate p50. Its overexpression and the resulting high level of p50 stimulates transcription of a broad array of tumor suppressors. Here we demonstrate that additional mechanisms are involved in the p50-mediated tumor-suppressive effect. p50 down-regulates expression of a major immune checkpoint inhibitor, the programmed cell death-ligand 1 (PD-L1), both in cells and in tumors. Importantly, the suppression is abrogated by overexpression of p65. This highlights the importance of the cellular quantities of the two different subunits of NF-ĸB which determine the composition of the dimer. While the putative p50 homodimer is tumor-suppressive, the "canonical" p50p65 heterodimer is oncogenic. We found that an additional mechanism is involved in the tumor-suppressive phenomenon: p50 up-regulates expression of the proinflammatory chemokines CCL3, CCL4, and CCL5, which in turn recruit into the tumors active natural killer (NK) cells and macrophages. Overall, p50 acts as a strong tumor suppressor via multiple mechanisms, including overexpression of tumor suppressors and modulation of the tumor microenvironment by recruiting active immune cells.

Entities:  

Keywords:  NF-ĸB p50; PD-L1; chemokines; tumor suppression; ubiquitin ligase KPC1

Mesh:

Substances:

Year:  2020        PMID: 33168738      PMCID: PMC7703627          DOI: 10.1073/pnas.2019604117

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma.

Authors:  G Akiri; M M Cherian; S Vijayakumar; G Liu; A Bafico; S A Aaronson
Journal:  Oncogene       Date:  2009-04-20       Impact factor: 9.867

Review 2.  NF-κB, an active player in human cancers.

Authors:  Yifeng Xia; Shen Shen; Inder M Verma
Journal:  Cancer Immunol Res       Date:  2014-09       Impact factor: 11.151

3.  IKKalpha controls p52/RelB at the skp2 gene promoter to regulate G1- to S-phase progression.

Authors:  Günter Schneider; Dieter Saur; Jens T Siveke; Ralph Fritsch; Florian R Greten; Roland M Schmid
Journal:  EMBO J       Date:  2006-08-10       Impact factor: 11.598

Review 4.  Molecular basis of NF-κB signaling.

Authors:  Johanna Napetschnig; Hao Wu
Journal:  Annu Rev Biophys       Date:  2013-03-11       Impact factor: 12.981

5.  Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression.

Authors:  Sanjeev Shukla; Gregory T MacLennan; Pingfu Fu; Jigar Patel; Susan R Marengo; Martin I Resnick; Sanjay Gupta
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

6.  Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors:  Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

7.  Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain.

Authors:  K Ohbo; T Suda; M Hashiyama; A Mantani; M Ikebe; K Miyakawa; M Moriyama; M Nakamura; M Katsuki; K Takahashi; K Yamamura; K Sugamura
Journal:  Blood       Date:  1996-02-01       Impact factor: 22.113

Review 8.  Modulation of NF-κB signalling by microbial pathogens.

Authors:  Masmudur M Rahman; Grant McFadden
Journal:  Nat Rev Microbiol       Date:  2011-03-08       Impact factor: 60.633

Review 9.  Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy.

Authors:  Anna E Vilgelm; Ann Richmond
Journal:  Front Immunol       Date:  2019-02-27       Impact factor: 7.561

10.  Metadherin, p50, and p65 expression in epithelial ovarian neoplasms: an immunohistochemical study.

Authors:  Ioanna Giopanou; Vasiliki Bravou; Panagiotis Papanastasopoulos; Ioannis Lilis; Panagiotis Aroukatos; Dionysios Papachristou; Sophia Kounelis; Helen Papadaki
Journal:  Biomed Res Int       Date:  2014-05-22       Impact factor: 3.411

View more
  5 in total

1.  A short binding site in the KPC1 ubiquitin ligase mediates processing of NF-κB1 p105 to p50: A potential for a tumor-suppressive PROTAC.

Authors:  Gilad Goldhirsh; Yelena Kravtsova-Ivantsiv; Gandhesiri Satish; Tamar Ziv; Ashraf Brik; Aaron Ciechanover
Journal:  Proc Natl Acad Sci U S A       Date:  2021-12-07       Impact factor: 12.779

Review 2.  Emerging roles of the HECT-type E3 ubiquitin ligases in hematological malignancies.

Authors:  Vincenza Simona Delvecchio; Claudia Fierro; Sara Giovannini; Gerry Melino; Francesca Bernassola
Journal:  Discov Oncol       Date:  2021-10-08

3.  Transcription Coactivator BCL3 Acts as a Potential Regulator of Lipid Metabolism Through the Effects on Inflammation.

Authors:  Shuo Zhang; Jingtao Gao; Shibo Liu; Lu Yu; Wen Zhang; Yinming Liang; Hui Wang
Journal:  J Inflamm Res       Date:  2021-09-23

4.  Panels of mRNAs and miRNAs for decoding molecular mechanisms of Renal Cell Carcinoma (RCC) subtypes utilizing Artificial Intelligence approaches.

Authors:  Seyed Mahdi Hosseiniyan Khatibi; Mohammadreza Ardalan; Mohammad Teshnehlab; Sepideh Zununi Vahed; Saeed Pirmoradi
Journal:  Sci Rep       Date:  2022-09-30       Impact factor: 4.996

5.  Assessment of genetic susceptibility to multiple primary cancers through whole-exome sequencing in two large multi-ancestry studies.

Authors:  Taylor B Cavazos; Linda Kachuri; Rebecca E Graff; Jovia L Nierenberg; Khanh K Thai; Stacey Alexeeff; Stephen Van Den Eeden; Douglas A Corley; Lawrence H Kushi; Thomas J Hoffmann; Elad Ziv; Laurel A Habel; Eric Jorgenson; Lori C Sakoda; John S Witte
Journal:  BMC Med       Date:  2022-10-06       Impact factor: 11.150

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.